vs
Apellis Pharmaceuticals, Inc.（APLS）与OFG BANCORP（OFG）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是OFG BANCORP的1.1倍（$199.9M vs $184.3M），OFG BANCORP净利率更高（30.3% vs -29.5%，领先59.8%），OFG BANCORP同比增速更快（0.9% vs -5.9%），OFG BANCORP自由现金流更多（$199.3M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 2.8%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
OFG Bancorp成立于1964年，总部位于波多黎各圣胡安，是东方银行的金融控股公司。公司通过东方银行、东方金融服务有限责任公司、东方保险有限责任公司等核心子公司，主要面向波多黎各和美属维尔京群岛市场，提供多元化的零售与商业银行、贷款、财富管理相关产品、服务及技术解决方案。
APLS vs OFG — 直观对比
营收规模更大
APLS
是对方的1.1倍
$184.3M
营收增速更快
OFG
高出6.8%
-5.9%
净利率更高
OFG
高出59.8%
-29.5%
自由现金流更多
OFG
多$213.6M
$-14.3M
两年增速更快
APLS
近两年复合增速
2.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $184.3M |
| 净利润 | $-59.0M | $55.9M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 25.7% |
| 净利率 | -29.5% | 30.3% |
| 营收同比 | -5.9% | 0.9% |
| 净利润同比 | -62.2% | 11.0% |
| 每股收益（稀释后） | $-0.40 | $1.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSOFG
| Q4 25 | $199.9M | $184.3M | ||
| Q3 25 | $458.6M | $186.2M | ||
| Q2 25 | $178.5M | $182.4M | ||
| Q1 25 | $166.8M | $178.6M | ||
| Q4 24 | $212.5M | $182.7M | ||
| Q3 24 | $196.8M | $174.7M | ||
| Q2 24 | $199.7M | $179.8M | ||
| Q1 24 | $172.3M | $174.4M |
净利润APLSOFG
| Q4 25 | $-59.0M | $55.9M | ||
| Q3 25 | $215.7M | $51.8M | ||
| Q2 25 | $-42.2M | $51.8M | ||
| Q1 25 | $-92.2M | $45.6M | ||
| Q4 24 | $-36.4M | $50.3M | ||
| Q3 24 | $-57.4M | $47.0M | ||
| Q2 24 | $-37.7M | $51.1M | ||
| Q1 24 | $-66.4M | $49.7M |
营业利润率APLSOFG
| Q4 25 | -25.6% | 25.7% | ||
| Q3 25 | 48.7% | 33.0% | ||
| Q2 25 | -18.6% | 36.1% | ||
| Q1 25 | -50.0% | 33.3% | ||
| Q4 24 | -12.3% | 28.9% | ||
| Q3 24 | -24.0% | 35.4% | ||
| Q2 24 | -14.7% | 39.6% | ||
| Q1 24 | -36.0% | 38.9% |
净利率APLSOFG
| Q4 25 | -29.5% | 30.3% | ||
| Q3 25 | 47.0% | 27.8% | ||
| Q2 25 | -23.6% | 28.4% | ||
| Q1 25 | -55.3% | 25.5% | ||
| Q4 24 | -17.1% | 27.6% | ||
| Q3 24 | -29.2% | 26.9% | ||
| Q2 24 | -18.9% | 28.4% | ||
| Q1 24 | -38.5% | 28.5% |
每股收益（稀释后）APLSOFG
| Q4 25 | $-0.40 | $1.27 | ||
| Q3 25 | $1.67 | $1.16 | ||
| Q2 25 | $-0.33 | $1.15 | ||
| Q1 25 | $-0.74 | $1.00 | ||
| Q4 24 | $-0.30 | $1.10 | ||
| Q3 24 | $-0.46 | $1.00 | ||
| Q2 24 | $-0.30 | $1.08 | ||
| Q1 24 | $-0.54 | $1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $1.0B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $1.4B |
| 总资产 | $1.1B | $12.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSOFG
| Q4 25 | $466.2M | $1.0B | ||
| Q3 25 | $479.2M | $740.3M | ||
| Q2 25 | $370.0M | $851.8M | ||
| Q1 25 | $358.4M | $710.6M | ||
| Q4 24 | $411.3M | $591.1M | ||
| Q3 24 | $396.9M | $680.6M | ||
| Q2 24 | $360.1M | $740.4M | ||
| Q1 24 | $325.9M | $754.4M |
总债务APLSOFG
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSOFG
| Q4 25 | $370.1M | $1.4B | ||
| Q3 25 | $401.2M | $1.4B | ||
| Q2 25 | $156.3M | $1.3B | ||
| Q1 25 | $164.2M | $1.3B | ||
| Q4 24 | $228.5M | $1.3B | ||
| Q3 24 | $237.1M | $1.3B | ||
| Q2 24 | $264.3M | $1.2B | ||
| Q1 24 | $266.7M | $1.2B |
总资产APLSOFG
| Q4 25 | $1.1B | $12.5B | ||
| Q3 25 | $1.1B | $12.2B | ||
| Q2 25 | $821.4M | $12.2B | ||
| Q1 25 | $807.3M | $11.7B | ||
| Q4 24 | $885.1M | $11.5B | ||
| Q3 24 | $901.9M | $11.5B | ||
| Q2 24 | $904.5M | $11.3B | ||
| Q1 24 | $831.9M | $11.2B |
负债/权益比APLSOFG
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $217.7M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $199.3M |
| 自由现金流率自由现金流/营收 | -7.1% | 108.1% |
| 资本支出强度资本支出/营收 | 0.1% | 10.0% |
| 现金转化率经营现金流/净利润 | — | 3.90× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $345.4M |
8季度趋势，按日历期对齐
经营现金流APLSOFG
| Q4 25 | $-14.2M | $217.7M | ||
| Q3 25 | $108.5M | $39.5M | ||
| Q2 25 | $4.4M | $35.9M | ||
| Q1 25 | $-53.4M | $83.1M | ||
| Q4 24 | $19.4M | $252.5M | ||
| Q3 24 | $34.1M | $58.1M | ||
| Q2 24 | $-8.3M | $95.1M | ||
| Q1 24 | $-133.0M | $61.0M |
自由现金流APLSOFG
| Q4 25 | $-14.3M | $199.3M | ||
| Q3 25 | $108.3M | $35.5M | ||
| Q2 25 | $4.4M | $31.8M | ||
| Q1 25 | $-53.4M | $78.7M | ||
| Q4 24 | $19.3M | $231.2M | ||
| Q3 24 | — | $51.8M | ||
| Q2 24 | $-8.4M | $90.4M | ||
| Q1 24 | $-133.3M | $54.8M |
自由现金流率APLSOFG
| Q4 25 | -7.1% | 108.1% | ||
| Q3 25 | 23.6% | 19.1% | ||
| Q2 25 | 2.5% | 17.4% | ||
| Q1 25 | -32.0% | 44.1% | ||
| Q4 24 | 9.1% | 126.5% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | -4.2% | 50.3% | ||
| Q1 24 | -77.3% | 31.4% |
资本支出强度APLSOFG
| Q4 25 | 0.1% | 10.0% | ||
| Q3 25 | 0.0% | 2.1% | ||
| Q2 25 | 0.0% | 2.3% | ||
| Q1 25 | 0.0% | 2.4% | ||
| Q4 24 | 0.0% | 11.7% | ||
| Q3 24 | 0.0% | 3.6% | ||
| Q2 24 | 0.0% | 2.6% | ||
| Q1 24 | 0.2% | 3.5% |
现金转化率APLSOFG
| Q4 25 | — | 3.90× | ||
| Q3 25 | 0.50× | 0.76× | ||
| Q2 25 | — | 0.69× | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 5.02× | ||
| Q3 24 | — | 1.24× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.23× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
OFG
暂无分部数据
